The Norwegian Nucleoside Analogue Stop Study

PHASE4CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

September 20, 2018

Primary Completion Date

January 31, 2023

Study Completion Date

January 31, 2023

Conditions
Hepatitis B, Chronic
Interventions
OTHER

Stop of therapy

The active intervention is to stop antiviral therapy, and delay re-start in the high-threshold group.

Trial Locations (11)

Unknown

Hvidovre Hospital, Copenhagen

St Paul Hospital Millennium Medical College, Addis Ababa

Ålesund Hospital, Ålesund

Bodø Hospital, Bodø

Drammen Hospital, Drammen

Akershus University Hospital, Lørenskog

Oslo University Hospital, Oslo

Bærum Hospital, Sandvika

Stavanger University Hospital, Stavanger

Tønsberg Hospital, Tønsberg

Karonlinska University Hospital, Stockholm

All Listed Sponsors
collaborator

University Hospital, Akershus

OTHER

collaborator

Addis Ababa University

OTHER

collaborator

St. Paul's Hospital Millennium Medical College, Ethiopia

OTHER

collaborator

South-Eastern Norway Regional Health Authority, Norway

UNKNOWN

collaborator

Bærum Hospital, Norway

UNKNOWN

collaborator

Drammen Hospital, Norway

UNKNOWN

collaborator

Tønsberg Hospital, Norway

UNKNOWN

collaborator

Helse Stavanger HF

OTHER_GOV

collaborator

Ålesund Hospital, Norway

UNKNOWN

collaborator

Bodø Hospital, Norway

UNKNOWN

collaborator

Hvidovre University Hospital

OTHER

collaborator

Karolinska University Hospital

OTHER

lead

Oslo University Hospital

OTHER

NCT03681132 - The Norwegian Nucleoside Analogue Stop Study | Biotech Hunter | Biotech Hunter